Moreover, the value of molecular studies described herein—including DNA methylation profiling, analysis of the degree of genomic instability, and evaluation of specific secondary genomic alterations, such as CDKN2A/B deletions—in classifying KAT6B/A::KANSL1 uterine sarcoma into clinically relevant groups needs to be studied in larger cohorts. The gene discussed is CDKN2A; the disease is uterine corpus sarcoma.